DOCSLIB.ORG

Unravelling Aldolase C Moonlighting Functions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Unravelling Aldolase C Moonlighting Functions European School of Molecular Medicine (SEMM) Naples site Università degli Studi di Napoli “Federico II” PhD in Molecular Medicine –VI/XXIV cycle Human Genetics Unravelling aldolase C moonlighting functions: a multi-task approach PhD candidate: Simona Langellotti Tutor: Prof. Francesco Salvatore Internal Supervisor: Prof. Stefania Orrù External Supervisor: Prof. Francisco Ernesto Baralle Academic Year 2011/2012 TABLE OF CONTENTS LIST OF ABBREVIATIONS ...............................................................................................3 FIGURE INDEX ...................................................................................................................4 TABLES INDEX ...................................................................................................................5 ABSTRACT ..........................................................................................................................6 SPECIFIC AIMS ..................................................................................................................9 Chapter 1 ............................................................................................................................10 INTRODUCTION ...............................................................................................................10 1.1 The aldolase system..........................................................................................10 1.2 Aldolase Isozymes. ............................................................................................11 1.3 Protein structure. ................................................................................................15 1.4 The aldolase C isozyme....................................................................................17 1.5 Aldolase C gene expression during development.........................................19 1.6 Aldolase “moonlighting” functions and involvement of aldolase C in the physiology of the CNS.......................................................................................20 1.7 Aldolase C and the NF-L mRNA: a possible involvement in neurodegeneration. ............................................................................................24 1.8 Proteomics and the functional proteomic approach. ....................................27 1.9 Monoclonal antibodies: features and production...........................................30 Chapter 2 ............................................................................................................................34 MATERIALS AND METHODS ........................................................................................34 2.1 Standard solutions. ............................................................................................34 2.2 Enzymes. .............................................................................................................34 2.3 Synthetic oligonucleotides. ...............................................................................35 2.4 Radioactive isotope............................................................................................35 2.5 Bacterial culture..................................................................................................35 2.6 Cell culture...........................................................................................................35 2.7 DNA preparation.................................................................................................36 2.7.1 Small scale preparation of plasmid DNA from bacterial cultures. ..............36 2.7.2 Large scale preparations of plasmid DNA from bacterial cultures. ............37 2.8 RNA extraction from cultured cells. .................................................................38 2.9 Estimation of nucleic acid concentration. .......................................................38 2.10 cDNA synthesis. .................................................................................................39 2.11 PCR amplification of selected DNA fragments..............................................39 2.12 Enzymatic modification of DNA........................................................................44 2.12.1 Restriction enzymes...........................................................................................44 2.12.2 T4 DNA ligase.....................................................................................................44 2.13 Agarose gel electrophoresis of DNA...............................................................45 2.14 Elution and purification of DNA fragments from agarose gels. ...................45 2.15 Preparation of bacterial competent cells. .......................................................46 2.16 Transformation of bacteria................................................................................46 2.17 Cell culture transfections...................................................................................47 2.18 Anti-FLAG immunoprecipitation (IP) and protein(s) co-immunoprecipitation (co-IP)...................................................................................................................47 2.19 SDS-PAGE and In situ hydrolysis of proteins................................................48 2.20 Protein identification by mass spectrometry and bioinformatics.................49 2.21 Protein extraction from cells or tissues...........................................................50 2.22 Western blotting (immunoblotting)...................................................................51 2.23 In vitro transcription............................................................................................52 2.24 Protein-RNA co-immunoprecipitation assay. .................................................54 2.25 Real Time PCR...................................................................................................55 2.26 Expression and purification of fusion proteins...............................................56 1 2.27 RNA EMSA..........................................................................................................57 2.28 UV cross-linking experiments...........................................................................58 2.29 Elisa assay of biotinylated peptides. ...............................................................59 2.30 Aldolase C immunoprecipitation using the 9F mAb......................................61 Chapter 3 ............................................................................................................................62 RESULTS AND DISCUSSION........................................................................................62 PART A...............................................................................................................................62 A functional proteomics approach to identify novel molecular interactors of the aldolase C protein: from a new binding partner of aldolase C to the study of its putative RNA-binding ability. ...........................................................................................62 3A.1 Immunoprecipitation of 3xFLAG-tagged aldolase C protein in Neuro2a cells.......................................................................................................................62 3A.2 Mass spectrometry identification of aldolase C interacting proteins. .........66 3A.3 Validation of the interaction between aldolase C and the 14-3-3 γ protein by Western Blotting............................................................................................72 3A.4 The NF-L mRNA: a possible functional link between aldolase C and the 14-3-3 γ protein...................................................................................................73 3A.4.1 The NF-L RNA co-immunoprecipitates with aldolase C...............................75 3A.4.2 EMSA and supershift tests confirm the presence of aldolase C within an NF-L mRNA-binding complex but demonstrate that no direct binding occurs between aldolase C and this RNA target...........................................77 3A.4.3 The protein-RNA UV cross-linking assay confirm the absence of direct binding between aldolase C and the NF-L mRNA. .......................................82 3A.5 Evaluation of aldolase C expression response after NGF administration in the PC12 cell line. ..............................................................................................84 PART B …………………………………………………………………………………...88 Antigenic characterization of monoclonal anti-human aldolase C antibodies. ........88 3B.1 Monoclonal antibodies preparation. ................................................................89 3B.2 Isozyme specificity of the 9F and 2A mAbs. ..................................................89 3B.3 Identification of the aldolase C protein “macrodomain” including the specific antigen recognized by the 9F and 2A mAbs. ..................................91 3B.4 Aldolase A vs aldolase C: sequence alignment of residues 1-100. ...........95 3B.5 “ElliPro” analysis of the tertiary structure of the human aldolase C protein. ...............................................................................................................................96 3B.6 ELISA screening of biotinylated aldolase C peptides.................................102 3B.7 Epitope mapping in eukaryotic cells confirms specificity of the 9F and 2A mAbs for peptide 85-102.................................................................................105
Load more

Recommended publications
  • Figure S1. Quality Control Validation of MS Data. (A‑C) Mass Error Distribution of All Peptides Identified in the Acetylome
    Figure S1. Quality control validation of MS data. (A‑C) Mass error distribution of all peptides identified in the acetylome, succi- nylome and quantitative proteome, respectively. (D‑F) Length distribution of peptides identified in the acetylome, succinylome and quantitative proteome, respectively. Figure S2. Comparison of modification level between breast cancer tissue and normal tissue. Comparison of acetylation level (A) and succinylation level (B) between breast cancer tissue and normal tissue. Data are medians and were analyzed using Wilcoxon Signed Rank Test. **P<0.01. Table SI. Protein sites whose acetylation and succinylation levels were both significantly upregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein name Modification site P54868 HMCS2 310K Q15063 POSTN 549K Q99715 COCA1 1601K P51572 BAP31 72K P07237 PDLA1 328K Q06830 PRDX1 192K P48735 IDHP 180K P30101 PDIA3 417K P0DMV9 HS71B 526K Q01995 TAGL 21K P06748 NPM1 27K Q00325 MPCP 209K P00488 F13A 69K P02545 LMNA 260K P08133 ANXA6 478K P02452 CO1A1 751K Table SII. Protein sites whose acetylation and succinylation levels were both significantly downregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein name Modification site RET4 P02753 30K PSG2 P07585 142K HBA P69905 12K IGKC P01834 80K HBA P69905 8K Table SIII. All proteins whose expression level were significantly upregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein description
    [Show full text]
  • Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’
    Journal of Neuromuscular Diseases 8 (2021) 401–417 401 DOI 10.3233/JND-200621 IOS Press Systematic Review Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’ A. Mantaa,b, S. Spendiffb, H. Lochmuller¨ b,c,d,e,f and R. Thompsonb,∗ aFaculty of Medicine, University of Ottawa, Ottawa, ON, Canada bChildren’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada cDepartment of Neuropediatrics and Muscle Disorders, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany dCentro Nacional de An´alisis Gen´omico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, Spain eDivision of Neurology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada f Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada Abstract. Background: Metabolic myopathies are a heterogenous group of muscle diseases typically characterized by exercise intoler- ance, myalgia and progressive muscle weakness. Effective treatments for some of these diseases are available, but while our understanding of the pathogenesis of metabolic myopathies related to glycogen storage, lipid metabolism and ␤-oxidation is well established, evidence linking treatments with the precise causative genetic defect is lacking. Objective: The objective of this study was to collate all published evidence on pharmacological therapies for the aforemen- tioned metabolic myopathies and link this to the genetic mutation in a format amenable to databasing for further computational use in line with the principles of the “treatabolome” project. Methods: A systematic literature review was conducted to retrieve all levels of evidence examining the therapeutic efficacy of pharmacological treatments on metabolic myopathies related to glycogen storage and lipid metabolism.
    [Show full text]
  • Aldolase C (C-Terminus Specific) Data Sheet
    Aldolase C (C-terminus Specific) Data Sheet Catalog Number: MO22157 Host: Mouse Product Type: Monoclonal IgG1 Species Human, horse, cow, pig, Affinity Purified Antibody Reactivity: chicken, rat, mouse Immunogen Sequence: C-terminal sequence Format: Liquid, 100 ul aliquot KYEGSGEDGGAAAQSLYIANHAY Concentration: 1 mg/ml HGNC name for this protein is ALDOC Applications: Immunofluorescence/Immunocytochemistry: 1:500-1:1,000 Immunohistochemistry: 1: 500-1:1,000 Western Blot: 1:1,000 Dilutions listed as a recommendation. Optimal dilution should be determined by investigator. Storage: Antibody can also be aliquoted and stored frozen at -20° C to -70° C in a manual defrost freezer for six months without detectable loss of activity. The antibody can be stored at 2° - 8° C for 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles. Application Notes Description/Data: Aldolase A is generally considered to be a muscle enzyme. Northern analysis of cultured cells suggests that it is present in both neurons and glia. Aldolase C shares 81% amino acid identity with aldolase A and 70% identity with aldolase B. Earlier studies using isozyme-specific antibodies report its location in gray matter astrocytes and cells of the pia mater. In situ hybridization of mouse central nervous system using isozyme-specific probes revealed that aldolase A and C are expressed in complementary cell types: aldolase A mRNA is found in neurons; aldolase C message is detected in astrocytes, some cells of the pia mater, and Purkinje cells. Aldolase C can in some situations be used as an astrocyte marker. However Purkinje cells of the cerebellum contain high levels of the enzyme, so the enzyme is not totally astrocyte specific.
    [Show full text]
  • Datasheet: VPA00226
    Datasheet: VPA00226 Description: RABBIT ANTI ALDOA Specificity: ALDOA Format: Purified Product Type: PrecisionAb™ Polyclonal Isotype: Polyclonal IgG Quantity: 100 µl Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse, Rat Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation Rabbit Ig fraction prepared by ammonium sulphate precipitation Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen KLH conjugated synthetic peptide between 66-95 amino acids from the N-terminal region of human ALDOA External Database UniProt: Links P04075 Related reagents Entrez Gene: 226 ALDOA Related reagents Page 1 of 2 Synonyms ALDA Specificity Rabbit anti Human ALDOA antibody recognizes fructose-bisphosphate aldolase A, also known as epididymis secretory sperm binding protein Li 87p, fructose-1,6-bisphosphate triosephosphate-lyase, lung cancer antigen NY-LU-1 and muscle-type aldolase. Encoded by the ALDOA gene, fructose-bisphosphate aldolase A is a glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate.
    [Show full text]
  • Maladies Convention Mal
    maladies métaboliques monogéniques héréditaires rares 1 avenant à la convention avec les centres de référence – annexe OMIM # FULL NAME A. disorders of amino acid metabolism 1 261600 classical phenylketonuria and hyperphenylala- ninemia 2 261640 phenylketonuria due to PTPS deficiency 3 261630 phenylketonuria due to DHPR deficiency 4 264070 phenylketonuria due to PCD deficiency 5 128230 DOPA-responsive dystonia (TH, SPR, GCH1) 6 248600 leucinose, maple syrup urine disease (MSUD) 7 276700 tyrosinemia type 1 8 276600 tyrosinemia type 2 9 276710 tyrosinemia type 3 10 203500 alkaptonuria 11 236200 homocystinuria, B6 responsive and non responsive 12 236250 homocystinuria due to MTHFR deficiency 13 236270-250940 homocystinuria-megaloblastic anemia Cbl E & G type 14 250850 methionine S-adenosyltransferase deficiency 15 606664 glycine N-methyltransferase deficiency 16 180960 S-adenosylhomocystine hydrolase deficiency 17 237300 hyperammonemia due to CPS deficiency 18 311250 hyperammonemia due to OTC deficiency 19 215700 citrullinemia type I 20 605814-603471 citrullinemia type II 21 207900 argininosuccinic aciduria (ASL deficiency) 22 207800 argininemia (arginase deficiency) 23 237310 hyperammonemia due to NAGS deficiency 24 238970 hyperornithinemia, hyperammonemia, homocitrulli- nuria (HHH) 25 222700 lysinuric protein intolerance 26 258870 gyrate atrophy, B6 responsive or non responsive 27 238700 hyperlysinemia (alpha-aminoadipic semialdehyde synthase deficiency) 28 238300-330-310 non ketotic hyperglycinaemia 29 234500 hartnup disorder 30 601815-172480
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • Table S1. Disease Classification and Disease-Reaction Association
    Table S1. Disease classification and disease-reaction association Disorder class Associated reactions cross Disease Ref[Goh check et al.
    [Show full text]
  • The Stochastic Human Red Blood Cell Model and Its Applications
    RESEARCH The Stochastic Human Red Blood Cell Model and Its Applications Archita Biswas1, Pawan K Dhar1, Girja Kaushal2, Usha Kumari3, Kalaiarasan Ponnusamy* 1Synthetic Biology group, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India 2Center of Innovative and Applied Bioprocessing, Mohali, Punjab, India 3Faculty of Medicine, AIMST University, Malaysia. *Corresponding author’s email: [email protected] ABSTRACT Red blood cells (RBCs) form the bulk of the blood volume for delivering oxygen and nutrients to various cells in the body. Several studies have focused on the RBCs to understand its metabolic activities in normal and abnormal conditions. However, an integrated view of the red blood cell, as a system of molecular fluctuations, is still lacking. The RBC metabolic wiring comprises four key pathways, i.e. Glycolysis, Pentose Phosphate, Purine salvage pathway and Glutathione pathway. Here we present an integrated metabolic pathway model of the human red blood cell by including first three pathways due to their significant presence and interaction. Furthermore, the stochastic model of RBCs metabolic pathways has been extended to include explaining abnormal conditions in the form of Pyruvate Kinase and Aldolase A deficiencies. By studying metabolite changes in-silico, four biomarkers were found to represent two genetic mutations, i.e., 2-phosphoglycerate & phosphoenol pyruvate changes for Pyruvate kinase deficiency and fructose-1-6-bisphosphate & xylulose-5-phosphate for Aldolase A deficiency. The virtual RBC model has the potential for more clinical applications and can be scaled up to include additional regulatory and metabolic content. KEYWORDS: Virtual Cell, stochastic model, RBC, ns, Pyruvate kinase, Aldolase A deficiency. Citation: Biswas A et al (2018) The Stochastic human red blood cell model and its applications.
    [Show full text]
  • In This Table Protein Name, Uniprot Code, Gene Name P-Value
    Supplementary Table S1: In this table protein name, uniprot code, gene name p-value and Fold change (FC) for each comparison are shown, for 299 of the 301 significantly regulated proteins found in both comparisons (p-value<0.01, fold change (FC) >+/-0.37) ALS versus control and FTLD-U versus control. Two uncharacterized proteins have been excluded from this list Protein name Uniprot Gene name p value FC FTLD-U p value FC ALS FTLD-U ALS Cytochrome b-c1 complex P14927 UQCRB 1.534E-03 -1.591E+00 6.005E-04 -1.639E+00 subunit 7 NADH dehydrogenase O95182 NDUFA7 4.127E-04 -9.471E-01 3.467E-05 -1.643E+00 [ubiquinone] 1 alpha subcomplex subunit 7 NADH dehydrogenase O43678 NDUFA2 3.230E-04 -9.145E-01 2.113E-04 -1.450E+00 [ubiquinone] 1 alpha subcomplex subunit 2 NADH dehydrogenase O43920 NDUFS5 1.769E-04 -8.829E-01 3.235E-05 -1.007E+00 [ubiquinone] iron-sulfur protein 5 ARF GTPase-activating A0A0C4DGN6 GIT1 1.306E-03 -8.810E-01 1.115E-03 -7.228E-01 protein GIT1 Methylglutaconyl-CoA Q13825 AUH 6.097E-04 -7.666E-01 5.619E-06 -1.178E+00 hydratase, mitochondrial ADP/ATP translocase 1 P12235 SLC25A4 6.068E-03 -6.095E-01 3.595E-04 -1.011E+00 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 MIC J3QTA6 CHCHD6 1.090E-04 -5.913E-01 2.124E-03 -5.948E-01 Protein kinase C and casein Q9BY11 PACSIN1 3.837E-03 -5.863E-01 3.680E-06 -1.824E+00 kinase substrate in neurons protein 1 Tubulin polymerization- O94811 TPPP 6.466E-03 -5.755E-01 6.943E-06 -1.169E+00 promoting protein MIC C9JRZ6 CHCHD3 2.912E-02 -6.187E-01 2.195E-03 -9.781E-01 Mitochondrial 2-
    [Show full text]
  • 6 the Glycogen Storage Diseases and Related Disorders
    6 The Glycogen Storage Diseases and Related Disorders G. Peter A. Smit, Jan Peter Rake, Hasan O. Akman, Salvatore DiMauro 6.1 The Liver Glycogenoses – 103 6.1.1 Glycogen Storage Disease Type I (Glucose-6-Phosphatase or Translocase Deficiency) – 103 6.1.2 Glycogen Storage Disease Type III (Debranching Enzyme Deficiency) – 108 6.1.3 Glycogen Storage Disease Type IV (Branching Enzyme Deficiency) – 109 6.1.4 Glycogen Storage Disease Type VI (Glycogen Phosphorylase Deficiency) – 111 6.1.5 Glycogen Storage Disease Type IX (Phosphorylase Kinase Deficiency) – 111 6.1.6 Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency) – 112 6.2 The Muscle Glycogenoses – 112 6.2.1 Glycogen Storage Disease Type V (Myophosphorylase Deficiency) – 113 6.2.2 Glycogen Storage Disease Type VII (Phosphofructokinase Deficiency) – 113 6.2.3 Phosphoglycerate Kinase Deficiency – 114 6.2.4 Glycogen Storage Disease Type X (Phosphoglycerate Mutase Deficiency) – 114 6.2.5 Glycogen Storage Disease Type XII (Aldolase A Deficiency) – 114 6.2.6 Glycogen Storage Disease Type XIII (E-Enolase Deficiency) – 115 6.2.7 Glycogen Storage Disease Type XI (Lactate Dehydrogenase Deficiency) – 115 6.2.8 Muscle Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency) – 115 6.3 The Generalized Glycogenoses and Related Disorders – 115 6.3.1 Glycogen Storage Disease Type II (Acid Maltase Deficiency) – 115 6.3.2 Danon Disease – 116 6.3.3 Lafora Disease – 116 References – 116 102 Chapter 6 · The Glycogen Storage Diseases and Related Disorders Glycogen Metabolism Glycogen is a macromolecule composed of glucose viding glucose and glycolytic intermediates (. Fig. 6.1). units.
    [Show full text]
  • A Review of Isozymes in Cancer1
    Cancer Research VOLUME31 NOVEMBER 1971 NUMBER11 [CANCER RESEARCH 31, 1523-1542, November 1971] A Review of Isozymes in Cancer1 Wayne E. Criss Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida 32601 TABLE OF CONTENTS postulated role for that particular isozymic system in cellular metabolism. Summary 1523 Introduction 1523 Normal enzyme differentiation 1523 INTRODUCTION Tumor enzyme differentiation 1524 Isozymes 1524 Normal Enzyme Differentiation DNA polymerase 1524 Enzyme differentiation is the process whereby, during the Hexokinase 1525 Fructose 1,6-diphosphatase 1525 development of an organ in an animal, the organ acquires the quantitative and qualitative adult enzyme patterns (122). Key Aldolase 1526 pathway enzymes in several metabolic processes have been Pyruvate kinase 1527 found to undergo enzymatic differentiation. The enzymes Láclatedehydrogenase 1527 Isocitrate dehydrogenase 1527 involved in nitrogen metabolism, and also in urea cycle Malate dehydrogenase 1528 metabolism (180), are tyrosine aminotransferase (123, 151, Glycerol phosphate dehydrogenase 1529 330, 410), tryptophan pyrrolase (261), serine dehydratase Glutaminase 1529 (123, 410), histidine ammonia lyase (11), and aspartate Aspartate aminotransferase 1530 aminotransferase (337, 388). The enzymes involved in nucleic Adenylate kinase 1531 acid metabolism are DNA polymerase (156, 277) and RNase (52). In glycolysis the enzymes are hexokinase-glucokinase Carbamyl phosphate synthetase 1531 Lactose synthetase 1533 (98, 389), galactokinase 30, aldolase (267, 315), pyruvate Discussion 1533 kinase (73, 386), and lactate dehydrogenase (67, 69). In References 1533 mitochondrial oxidation they are NADH oxidase, succinic oxidase, a-glycero-P oxidase, ATPase, cytochrome oxidase, and flavin content (84, 296). In glycogen metabolism the SUMMARY enzymes involved are UDPG pyrophosphorylase and UDPG glucosyltransferase (19).
    [Show full text]
  • Hereditary Fructose Intolerance Caused by a Nonsense Mutation Of
    Am. J. Hum. Genet. 47:562-567, 1990 Hereditary Fructose Intolerance Caused by a Nonsense Mutation of the Aldolase B Gene Susumu Kajihara,*,t Tsunehiro Mukait Yuji AraiT Misao Owadat Teruo Kitagawa4 and Katsuji Hori* *Department of Biochemistry, Saga Medical School, Saga, Japan; tNational Cardiovascular Center Research Institute, Osaka; and tDepartment of Pediatrics, Nihon University, Tokyo Summary The nucleotide sequence of a patient's aldolase B gene was determined and showed a substitution of a sin- gle nucleotide (C-OA) at position 720 in the coding region, which resulted in the 240th amino acid, a cys- teine, being changed to a stop codon (TGC-"TGA). By an allele-specific oligonucleotide probe and poly- merase chain reaction, the patient was shown to be homozygous for the mutation. To examine whether this mutation causes functional defect of the enzyme, the activity of the aldolase B from the patient, ex- pressed in Escherichia coli by using expression plasmid, was measured. No activity was observed, and the predicted product was recovered from E. coli expression plasmid, indicating that this nonsense mutation was the cause of aldolase B deficiency. Introduction al. 1987). Another type of aldolase deficiency, heredi- Aldolase is a glycolytic enzyme involved in the conver- tary fructose intolerance (HFI), was discovered 30 years sion of fructose-bisphosphate into glyceraldehyde-3- ago as idiosyncrasy toward fructose (Chambers and phosphate and dihydroxyacetone-1-phosphate. There Pratt 1956). The mutation affects aldolase B ofthe liver, are three isozymic forms for the enzyme: aldolase A, intestine, and kidney and is transmitted as an autosomal aldolase B, and aldolase C (Horecker et al.
    [Show full text]